论文部分内容阅读
目的:对新辅助化疗联合同步放化疗治疗中晚期鼻咽癌进行临床观察。方法:选取2013年6月-12月间于我院进行治疗的中晚期鼻咽癌患者120例,随机分为两组。对照组患者采取同期放化疗治疗,而实验组患者采取新辅助化疗联合同步放化疗治疗。后对两组患者临床疗效进行分析比较。结果:相较于对照组,实验组中中晚期鼻咽癌患者临床放化疗不良反应发生率较高,但2年远处转移发生率明显低于对照组,p<0.05。结论:给予中晚期鼻咽癌患者新辅助化疗联合同步放化疗治疗能降低远处转移发生率,但对患者损伤较大,应根据患者具体情况采取合适治疗方式,从而保障患者生命健康。
OBJECTIVE: To observe the clinical effect of neoadjuvant chemotherapy combined with concurrent radiochemotherapy on advanced nasopharyngeal carcinoma. Methods: A total of 120 patients with advanced nasopharyngeal carcinoma who were treated in our hospital from June to December 2013 were randomly divided into two groups. Patients in the control group received concurrent chemoradiotherapy while patients in the experimental group received neoadjuvant chemotherapy combined with concurrent chemoradiation. After comparing the clinical efficacy of two groups of patients. Results: Compared with the control group, the incidence of adverse reactions of radiotherapy and chemotherapy was higher in patients with advanced NPC in the experimental group, but the incidence of distant metastasis in 2 years was significantly lower than that of the control group (p <0.05). Conclusion: Neoadjuvant chemotherapy combined with concurrent chemoradiotherapy can reduce the incidence of distant metastasis in patients with advanced nasopharyngeal carcinoma. However, it is more damaging to the patients. Appropriate treatment should be taken according to the specific conditions of the patients so as to protect their life and health.